ClinicalTrials.gov
ClinicalTrials.gov Menu

CardioMEMS HF System Post Approval Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02279888
Recruitment Status : Active, not recruiting
First Posted : October 31, 2014
Last Update Posted : October 19, 2017
Sponsor:
Information provided by (Responsible Party):
St. Jude Medical

Brief Summary:
The purpose of the CardioMEMS HF System Post Approval Study (PAS) is to evaluate the use of the CardioMEMS HF System in patients with NYHA class III heart failure in a commercial setting.

Condition or disease Intervention/treatment
Heart Failure Left-Sided Heart Failure Congestive Heart Failure Device: CardioMEMS HF System

Study Type : Observational
Actual Enrollment : 1200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: CardioMEMS HF System Post Approval Study
Study Start Date : January 2015
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Group/Cohort Intervention/treatment
CardioMEMS HF System Group
Patients implanted with a CardioMEMS HF System.
Device: CardioMEMS HF System
Pulmonary artery pressure sensor




Primary Outcome Measures :
  1. freedom from device/system related complication [ Time Frame: two year ]
  2. freedom from pressure sensor failure [ Time Frame: two year ]
  3. heart failure hospitalization rate [ Time Frame: one year ]

Other Outcome Measures:
  1. all-cause mortality [ Time Frame: one year ]
  2. heart failure hospitalization or death rate [ Time Frame: one year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients with NYHA class III heart failure
Criteria

Inclusion Criteria:

  • Diagnosis of NYHA class III heart failure
  • At least 1 heart failure hospitalization within previous 12 months
  • Patients with reduced LVEF heart failure should be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless in the investigator's opinion, the patient is intolerant to beta blockers, ACE-I or ARB
  • BMI ≤ 35. Patients with BMI >35 will require their chest circumference to be measured at the axillary level. If > 65 inches the patient will not be eligible for the study.
  • Pulmonary artery branch diameter ≥ 7mm - (implant target artery - assessed during the right heart catheterization)

Exclusion Criteria:

  • Active infection
  • History of recurrent (> 1) pulmonary embolism or deep vein thrombosis
  • Inability to tolerate a right heart catheterization
  • A major cardiovascular event (e.g., myocardial infarction, open heart surgery, stroke, etc.) within previous 2 months
  • Cardiac resynchronization device (CRT) implanted within previous 3 months
  • Glomerular Filtration Rate (GFR) < 25 ml/min (obtained within 2 weeks of implant) who are non-responsive to diuretic therapy or who are on chronic renal dialysis
  • Congenital heart disease or mechanical right heart valve
  • Likely to undergo heart transplantation or VAD within the next 6 months
  • Known coagulation disorders
  • Hypersensitivity or allergy to aspirin, and/or clopidogrel

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02279888


Locations
United States, West Virginia
West Virginia Heart Institute
Morgantown, West Virginia, United States, 26505
Sponsors and Collaborators
St. Jude Medical
Investigators
Study Chair: Lynne Stevenson, MD Brigham and Women's

Responsible Party: St. Jude Medical
ClinicalTrials.gov Identifier: NCT02279888     History of Changes
Other Study ID Numbers: SJM-CIP-10035
First Posted: October 31, 2014    Key Record Dates
Last Update Posted: October 19, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by St. Jude Medical:
Pulmonary Artery Pressure Monitoring
Implantable Hemodynamic Monitor

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases